Introduction
6-Py ruvoyl-tetrahydropterin synthase (PTPS) is the second enzyme involved in the biosynthesis of tetrahy drobiopterin (BH4)' , the obligatory cofactor for the aromatic amino acid h ydroxylases 2 as well as for all types of nitric oxide synthases 3 • Defects in the PTPS are the most frequent and heterogeneous variants of BH4 deficiency<. Three different forms of PTPS deficiency can be distinguished: (i) A central or severe type, where patients do not have sufficient PTPS activity in the brain and in the liver. Patients with this type of defect suffer from neurotransmitter deficiency in the central nervous system (CNS) and elevated phenylalanine concentrations in blood and tissue. They need to be treated with BH4, L-Dopa, Carbidopa and 5-hydroxytryptophan to prevent irreversible brain damage. (ii) In the partial or peripheral type, patients do not have enough PTPS in the liver, but neurotransmitter biosy nthesis in the brain is normal. They have to be treated with BH4 monothera py or follow a phenylalanine low diet l. (iii) A transient form , where patients present clinical symptoms only in the neonatal period, has been described in a few cases".
Since the human liver cDNA was isolated?, it was § Autho r to whom correspondence s hould be addressed. possible to investigate the cDNA in primary skin fibroblasts from PTPS deficient p atients in orde r to find out the mutations causing the disease. In this work three new mutations, a missense mutation and two deletions, in two patients suffering from the severe type of PTPS deficiency are described. Furthermore, a summary of all mutations found so far in the eDNA of PTPS deficient patients and of the clinical data of these patients is given. We hope that it will become possible to differentiate between variants of PTPS deficiency by finding and characterizing the mutations.
Materials and Methods
Pterins in urine were measured by HPLC, a fter oxidation with manganese dioxide, a s described previously8.
The PTPS assay is based on the measureme nt of BH. derived from dihydroneopterin triphosphate (substrate) (110 flM) in the presence of NADPH (1 mM), NADH (l mM), DHPR (220 mU), magnesium (10 mM), sepiapterin reductase (5 mU), and TrisHCl buffer, pH 7.4 (0.1 M)9. Erythrocytes (50 fll) were suspended in 50 fll of 0.2 M Tris-HCl buffer, pH 7.4 and lysed by freezing and thawing. The sample was saturated with carbon monoxide for 1-2 min unde r slight shaking and 50 fll of the lysate were used for th e a ssay. The biopterin was measured fluorom etricall y by HPLC after oxidation with manganese dioxide at pH 1.0-1.5.
Primary skin fibroblasts were cultured in Dulbecco's Modified Eagle Medium (Gibco) containing 10% fetal calf serum (Gibco) and 50 units of penicillin plus 50 /lg/ml streptomycin. Fibroblast lysate preparations and PTPS acivity measurements of these extracts were performed as described elsewhere lO • -, Total RNA was isolated from confluent fibroblast cultures following a protocol using guanidiniumthiocyamate for cell lysis and subsequent centrifugation in cesium chloride solution II. With oligodeoxythymidine as a primer cDNA was synthesized from this total RNA IO • cDNA was PCR-amplified and directly sequenced using the dideoxynucleotide chain termination method (USB sequencing kit, version 2.0) according to Thony et al lO •
Case Reports
The history of the patients JRS and UT has been reported elsewhere l ? LL is the first child of healthy, non related parents. On the 5th day the Guthrie test was slightly elevated, and the controls on day 10 and 42 were, for plasma phenylalanine, in the high normal range. His early development was normal. At the age of 4.5 months he developed a tendency to opistotonus progressing later into frequent attacks of hypertonicity of the extremities. The serum phenylalanine rose to 2840 flmol/ l , and the BH4 loading test, as well as the pattern of urinary pterins confirmed the diagnosis of a defective BH" biosynthesis. The child was treated with a combination of BH., L-Dopa/ Carbidopa, and 5-hydroxytryptophan 12 • SS was diagnosed as hyperphenylalaninemic at the age of four days. Plasma phenylalanine ranged between 1220 and 2400 /lmol/1. At the age of 5 weeks the diagnostic test for BH4 deficiency was performed; the BH. loading test was positive, neopterin was increased, and biopterin was very low. Reduced PTPS activity in the patient's erythrocytes confirmed the diagnosis. SS has been on BH. and neurotransmitter therapy since the age of ten weeks. At the age of 12 years her intelligence quotient was 5413.
Results and Discussion Table 1 shows four PTPS deficient patients studied by our group (JRS, UT, LL and SS) with reduced PTPS activity in fibroblasts and erythrocytes. Three other patients described by Shintaku ls were all of the central type with reduced or absent activity of PTPS in the erythrocytes. In one patient with the central type of PTPS deficiency, described by Ashida et a1. 16 , the activity of the enzyme in fibroblasts and erythrocytes was 20-fold and 5-fold lower, respectively, than that of the controls. Serum phenylalanine concentrations were elevated in all PTPS deficient patients and in all cases initially low biopterin and high neopterin levels were detected. Five patients were found to be homozygous for the mutations R25Q, P87L. 11 14V, and two patients showed the same mutation P87S (Figure 1) . The other three patients harbor the compound heterozygote mutations R16C/K120 ~ stop, a V57 /K54 ~ stop and P87S/D96N. All mutations found in the cDNA of PTPS deficient patients are in highly conserved regions. The codon at position 87 sems to be a hot spot for mutations in the 435bp reading frame of the PTPS cDNA. Four of eight analyzed patients showed a mutation at this position.
PTPS deficient patients with loower PTPS activities in erythrocytes and in fibroblasts showed also higher serum phenylalanine levels, higher neopterin and lower biopterin levels. Data presented in Table  I and those from previous studies l ? suggested that patients with the peripheral type of PTPS deficiency presented intermediate biochemical abnormalities. Biochemical characterization including kinetic and crosslinking experiments will reveal structural and functional differences between mutant proteins and the wild type PTPS. There was so far no correlation between the phenotype and genotype.
